10.6084/M9.FIGSHARE.C.6317187
Mohammed A. Omair
Mohammed A.
Omair
King Saud University
Hanan Al Rayes
Hanan
Al Rayes
0000-0002-6322-0831
Riyadh Armed Forces Hospital
Joanne Khabsa
Joanne
Khabsa
0000-0002-4336-3501
American University of Beirut Medical Center
Sally Yaacoub
Sally
Yaacoub
American University of Beirut Medical Center
Sultana Abdulaziz
Sultana
Abdulaziz
King Fahad Hospital Jeddah
Ghada A. Al Janobi
Ghada A.
Al Janobi
Qatif Central Hospital
Abdulaziz Al Khalaf
Abdulaziz
Al Khalaf
King Saud University
Bader Al Mehmadi
Bader
Al Mehmadi
0000-0002-5609-9914
Majmaah University
Mahasin Al Nassar
Mahasin
Al Nassar
King Saud University
Faisal AlBalawi
Faisal
AlBalawi
King Fahd Medical City
Abdullah S. AlFurayj
Abdullah S.
AlFurayj
Ahmed Hamdan Al-Jedai
Ahmed Hamdan
Al-Jedai
Alfaisal University
Ministry of Health
Haya Mohammed Almalag
Haya Mohammed
Almalag
King Saud University
Hajer Yousef Almudaiheem
Hajer Yousef
Almudaiheem
Ministry of Health
Ali AlRehaily
Ali
AlRehaily
0000-0003-0661-7530
Security Forces Hospital
Mohammed A. Attar
Mohammed A.
Attar
Armed Forces Hospital
Lina El Kibbi
Lina
El Kibbi
0000-0003-1710-9996
Hussein Halabi
Hussein
Halabi
0000-0002-5174-8292
King Faisal Specialist Hospital & Research Centre
Manal Hasan
Manal
Hasan
0000-0001-9342-7887
Imam Abdulrahman Bin Faisal University
Jasvinder A. Singh
Jasvinder A.
Singh
University of Alabama at Birmingham
Birmingham VA Medical Center
Liana Fraenkel
Liana
Fraenkel
Berkshire Medical Center
Yale University
Berkshire Health Systems
Elie A. Akl
Elie A.
Akl
0000-0002-3444-8618
American University of Beirut
McMaster University
Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
Abstract Background The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). Methods The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. Results The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). Conclusion Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines.
Medicine
Genetics
Biotechnology
39999 Chemical Sciences not elsewhere classified
Ecology
20199 Astronomical and Space Sciences not elsewhere classified
Immunology
Cancer
Science Policy
111714 Mental Health
figshare
2022
2022-11-25
2022-11-25
Collection
10.1186/s41927-022-00301-y
CC BY 4.0